Description: Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
Home Page: www.scandiononcology.com
Symbion
Copenhagen,
2100
Denmark
Phone:
45 38 10 20 17
Officers
Name | Title |
---|---|
Mr. Jan Stenvang M.S., Ph.D. | Chief Scientific Officer |
Dr. Francois Regis Martelet M.D. | Chief Executive Officer |
Mr. Johnny Stilou M.S. | Chief Financial Officer |
Mr. Morten Nissen | General Counsel |
Mr. Mads Kronborg | Head of External Communication |
Dr. Lars Damstrup | Chief Medical Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0.1667 |
Price-to-Book MRQ: | 0.5143 |
Price-to-Sales TTM: | 233.6545 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 4 |